Meeting Overview | We are pleased to invite you to our satellite symposium “Practical Approaches to Non-Small Cell Lung Cancer Management in the Era of Personalized Therapy,” to be held on 6 July 2011 during the 14th World Conference on Lung Cancer in Amsterdam, the Netherlands. |
Date and Location | 6 July 2011
12.15-14.15
Lunch will be available for pick-up from 12.15-12.30
Plenary Hall
Amsterdam RAI
Europaplein 22
Amsterdam, the Netherlands |
Target Audience | Practical Approaches to Non-Small Cell Lung Cancer Management in the Era of Personalized Therapy is specifically designed for medical oncologists and other healthcare professionals involved and/or interested in the management of patients with lung cancer. |
 Educational Objectives |
Upon completion of this educational activity, participants should be able to:
• Define the clinical, histologic, and molecular factors that guide clinicians in selecting therapy for patients with NSCLC
|
• Outline appropriate treatment regimens for patients with NSCLC, focusing on how best to tailor therapeutic choices to patient characteristics such as tissue histology, presence or absence of molecular markers, and comorbidities
|
• Analyze available and emerging treatment options in advanced NSCLC, including maintenance therapy and second-line therapy and beyond
|
• Identify areas of uncertainty or controversy requiring further clarification regarding the use of patient and disease characteristics as guides for treatment selection at various stages of disease progression in the management of NSCLC
|
|
Faculty | Chairman
|
Román Pérez-Soler, MD
Montefiore Medical Center
Bronx, New York, United States
|
Faculty
|
Luis Paz-Ares, MD, PhD
Hospital Universitario Virgen del Rocío
Seville, Spain
|
Martin Reck, MD, PhD
Hospital Grosshansdorf
Grosshansdorf, Germany
|
| |
|
Mark A. Socinski, MD
University of North Carolina
Chapel Hill, North Carolina, United States
|
Jean-Charles Soria, MD, PhD
Gustave Roussy Institute
Villejuif, France
|
|
Agenda |
| 12.15 |
Lunch pick-up |
|
12.30
|
Welcome and introduction
Román Pérez-Soler, MD
|
|
12.40
|
Defining the unmet needs in non-small cell lung cancer
Jean-Charles Soria, MD, PhD
|
| 12.55 |
Clinical opinion poll |
|
13.00
|
Interactive clinical case—Personalizing first-line treatment in the absence of mutations
Martin Reck, MD, PhD
|
| 13.30 |
Clinical opinion poll |
|
13.35
|
Interactive clinical case—Incorporating EGFR mutation status into first-line therapy selection
Luis Paz-Ares, MD, PhD
|
| 13.50 |
Clinical opinion poll |
|
13.55
|
Interactive clinical case—Therapeutic decision making in the second-line
Mark A. Socinski, MD
|
|
14.10
|
Ask the experts
All Faculty, moderated by Román Pérez-Soler, MD
|
| 14.15 |
Adjourn |
|
DISCLOSURE OF CONFLICTS OF INTEREST | prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. |
Disclosure of unlabeled use of agents | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food & Drug Administration or the European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications and warnings. |
DISCLAIMER | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
SPONSORSHIP |
This activity is sponsored by prIME Oncology.
|
CONTINUING EDUCATION STATEMENT | prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
SUPPORT |
Support for this activity has been provided by an unrestricted educational grant from F. Hoffmann-La Roche Ltd.
|
FEE INFORMATION | There is no fee for this activity and preregistration is not required; however, space is limited. |
Statement | This presentation was selected by the 14th World Conference on Lung Cancer Programme Committee as an independent educational activity held in conjunction with the 14th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by the IASLC. |
|
